Stathmin Is Dispensable for Tumor Onset in Mice

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  D'Andrea, Sara ^a   Berton, Stefania ^a   Segatto, Ilenia ^a   Fabris, Linda ^a   Canzonieri, Vincenzo ^a   Colombatti, Alfonso ^a,b   Vecchione, Andrea ^c   Belletti, Barbara ^a   Baldassarre, Gustavo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRYLENE; CARCINOGEN; DIMETHYLBENZ[A]ANTHRACENE; GENOMIC DNA; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P53; RAS PROTEIN; STATHMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DNA EXTRACTION; FIBROBLAST; FIBROSARCOMA; GENOTYPE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; ONCOGENE RAS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CARCINOGENESIS; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GENES, RAS; HETEROZYGOTE; MICE; MICE, KNOCKOUT; NEOPLASMS; STATHMIN; TUMOR SUPPRESSOR PROTEIN P53;

MUS; PAPILLOMAVIRIDAE;

EID: 84866678646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045561     Document Type: Article

References (57)

1. Sobel A, Tashjian AH Jr, (1983) Distinct patterns of cytoplasmic protein phosphorylation related to regulation of synthesis and release of prolactin by GH cells. J Biol Chem 258: 10312-10324.
2. Belmont LD, Mitchison TJ, (1996) Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 8: 623-631.
3. Gigant B, Curmi PA, Martin-Barbey C, Charbaut E, Lachkar S, et al. (2000) The 4 A X-ray structure of a tubulin:stathmin-like domain complex. Cell 102: 809-816.
4. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104: 7564-7569.
5. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, et al. (2010) Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2: 43ra55.
6. Marklund U, Brattsand G, Shingler V, Gullberg M, (1993) Serine 25 of oncoprotein 18 is a major cytosolic target for the mitogen-activated protein kinase. J Biol Chem 268: 15039-15047.
7. Di Paolo G, Pellier V, Catsicas M, Antonsson B, Catsicas S, et al. (1996) The phosphoprotein stathmin is essential for nerve growth factor-stimulated differentiation. J Cell Biol 133: 1383-90.
8. Lovrić J, Dammeier S, Kieser A, Mischak H, Kolch W, (1998) Activated raf induces the hyperphosphorylation of stathmin and the reorganization of the microtubule network. J Biol Chem 273: 22848-22855.
9. Ng DC, Zhao TT, Yeap YY, Ngoei KR, Bogoyevitch MA, (2010) c-Jun N-terminal kinase phosphorylation of stathmin confers protection against cellular stress. J Biol Chem 285: 29001-29013.
10. Curmi PA, Maucuer A, Asselin S, Lecourtois M, Chaffotte A, et al. (1994) Molecular characterization of human stathmin expressed in Escherichia coli: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63). Biochem J 300: 331-338.
11. Gradin HM, Larsson N, Marklund U, Gullberg M, (1998) Regulation of microtubule dynamics by extracellular signals: cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells. J Cell Biol 140: 131-141.
12. Marklund U, Larsson N, Brattsand G, Osterman O, Chatila TA, et al. (1994) Serine 16 of oncoprotein 18 is a major cytosolic target for the Ca2+/calmodulin-dependent kinase-Gr Eur J Biochem. 225: 53-60.
13. Brattsand G, Marklund U, Nylander K, Roos G, Gullberg M, (1994) Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38. Eur J Biochem 220: 359-68.
14. Cassimeris L, (2002) The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 14: 18-24.
15. Rubin CI, Atweh GF, (2004) The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93: 242-250.
16. Belletti B, Baldassarre G, (2011) Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 15: 1249-1266.
17. Mistry SJ, Bank A, Atweh GF, (2005) Targeting stathmin in prostate cancer. Mol Cancer Ther 4: 1821-1829.
18. Zahedi K, Revelo MP, Barone S, Wang Z, Tehrani K, et al. (2006) Stathmin-deficient mice develop fibrosis and show delayed recovery from ischemic-reperfusion injury. Am J Physiol Renal Physiol 290: F1559-1567.
19. Zhang Y, Xiong J, Wang J, Shi X, Bao G, et al. (2008) Regulation of melanocyte apoptosis by Stathmin 1 expression. BMB Rep 41: 765-770.
20. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi MB, Vecchione A, et al. (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7: 51-63.
21. Belletti B, Pellizzari I, Berton S, Fabris L, Wolf K, et al. (2010) p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol 30: 2229-2240.
22. Schiappacassi M, Lovisa S, Lovat F, Fabris L, Colombatti A, et al. (2011) Role of T198 modification in the regulation of p27(Kip1) protein stability and function. PLoS One 6: e17673.
23. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM, (1991) Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem 266: 17747-17753.
24. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, et al. (2008) Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 19: 2003-2013.
25. Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S, et al. (2008) p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther 7: 1164-1175.
26. Li N, Jiang P, Du W, Wu Z, Li C, et al. (2011) Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci U S A 108: 12851-12856.
27. Park HJ, Gusarova G, Wang Z, Carr JR, Li J, et al. (2011) Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3: 21-34.
28. Tan HT, Wu W, Ng YZ, Zhang X, Yan B, et al. (2012) Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker. J Proteome Res 11: 1433-1445.
29. Misek DE, Chang CL, Kuick R, Hinderer R, Giordano TJ, et al. (2002) Transforming properties of a Q18->E mutation of the microtubule regulator Op18. Cancer Cell. 2: 217-228.
30. Holmfeldt P, Brännström K, Stenmark S, Gullberg M, (2006) Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18->e mutation in leukemic cells. Mol Biol Cell 17: 2921-2930.
31. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, et al. (1999) Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18: 5954-5958.
32. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, et al. (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490-2501.
33. Johnsen JI, Aurelio ON, Kwaja Z, Jörgensen GE, Pellegata NS, et al. (2000) p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 88: 685-691.
34. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, et al. (2007) Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 46: 759-768.
35. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, et al. (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558.
36. Alli E, Yang JM, Hait WN, (2007) Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26: 1003-1012.
37. Carney BK, Cassimeris L, (2010) Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53. Cancer Biol Ther 9: 699-709.
38. Schubart UK, Yu J, Amat JA, Wang Z, Hoffmann MK, et al. (1996) Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation. J Biol Chem 271: 14062-14066.
39. Martel G, Nishi A, Shumyatsky GP, (2008) Stathmin reveals dissociable roles of the basolateral amygdala in parental and social behaviors. Proc Natl Acad Sci U S A 105: 14620-14625.
40. Wexler H, Rosenberg SA, (1979) Pulmonary metastases from autochthonous 3-methylcholanthrene-induced murine tumors. J Natl Cancer Inst 63: 1393-1395.
41. García-Cao I, García-Cao M, Martín-Caballero J, Criado LM, Klatt P, et al. (2002) "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 21: 6225-6235.
42. Ozaki K, Sukata T, Yamamoto S, Uwagawa S, Seki T, et al. (1998) High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 58: 3806-3811.
43. Abel EL, Angel JM, Kiguchi K, DiGiovanni J, (2009) Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 4: 1350-1362.
44. Papaconstantinou AD, Shanmugam I, Shan L, Schroeder IS, Qiu C, et al. (2006) Gene expression profiling in the mammary gland of rats treated with 7,12-dimethylbenz[α]anthracene. Int J Cancer 118: 17-24.
45. Rounbehler RJ, Schneider-Broussard R, Conti CJ, Johnson DG, (2001) Myc lacks E2F1's ability to suppress skin carcinogenesis. Oncogene 30: 5341-5349.
46. Curmi PA, Gavet O, Charbaut E, Ozon S, Lachkar-Colmerauer S, et al. (1999) Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct Funct 24: 345-357.
47. Okazaki T, Himi T, Peterson C, Mori N, (1993) Induction of stathmin mRNA during liver regeneration. FEBS Lett 336: 8-12.
48. Puissant C, Mitev V, Lemnaouar M, Manceau V, Sobel A, et al. (1995) Stathmin gene expression in mammary gland and in Nb2 cells. Biol Cell 85: 109-115.
49. Hasegawa A, Hisatomi O, Yamamoto S, Ono E, Tokunaga F, (2007) Stathmin expression during newt retina regeneration. Exp Eye Res 85: 518-527.
50. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406.
51. Xi W, Rui W, Fang L, Ke D, Ping G, et al. (2009) Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 135: 837-846.
52. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, et al. (2011) Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 17: 3368-3377.
53. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
54. Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, et al. (2010) Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther 17: 780-791.
55. Mistry SJ, Bank A, Atweh GF, (2007) Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res 5: 773-782.
56. Shi X, Wang D, Ding K, Lu Z, Jin Y, et al. (2010) GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther 9: 640-650.
57. Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, et al. (2011) Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 123: 5-12.